博拓生物今年一季度归母净利润同比增长233.05%

新京报04-28

新京报讯（记者王卡拉）4月27日，博拓生物发布2024年一季报，报告期内实现营收1.36亿元，同比增长30.81%；归属于上市公司股东的净利润为3963.13万元，同比增长233.05%。归属于上市公司股东的扣除非经常性损益的净利润同比增长335.55%。2023年，受新冠疫情常态化后新冠检测试剂产品销售收入同比大幅减少的影响，博拓生物净利润同比大幅下滑。因市场需求发生变化，博拓生物部分生产设备...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2430054133?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-28 20:48","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2430054133","market":"sh","top_or_hot":-1,"title":"博拓生物今年一季度归母净利润同比增长233.05%","media":"新京报","content":"<div>\n<p>新京报讯（记者王卡拉）4月27日，博拓生物发布2024年一季报，报告期内实现营收1.36亿元，同比增长30.81%；归属于上市公司股东的净利润为3963.13万元，同比增长233.05%。归属于上市公司股东的扣除非经常性损益的净利润同比增长335.55%。2023年，受新冠疫情常态化后新冠检测试剂产品销售收入同比大幅减少的影响，博拓生物净利润同比大幅下滑。因市场需求发生变化，博拓生物部分生产设备...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042820500287badffa&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>博拓生物今年一季度归母净利润同比增长233.05%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n博拓生物今年一季度归母净利润同比增长233.05%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-28 20:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042820500287badffa&s=b><strong>新京报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>新京报讯（记者王卡拉）4月27日，博拓生物发布2024年一季报，报告期内实现营收1.36亿元，同比增长30.81%；归属于上市公司股东的净利润为3963.13万元，同比增长233.05%。归属于上市公司股东的扣除非经常性损益的净利润同比增长335.55%。2023年，受新冠疫情常态化后新冠检测试剂产品销售收入同比大幅减少的影响，博拓生物净利润同比大幅下滑。因市场需求发生变化，博拓生物部分生产设备...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042820500287badffa&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688767","symbol_name":"博拓生物","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042820500287badffa&s=b","article_id":"2430054133","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042820500287badffa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2430054133","pubTimestamp":1714308514,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"归属于上市公司股东的扣除非经常性损益的净利润同比增长335.55%。2023年，受新冠疫情常态化后新冠检测试剂产品销售收入同比大幅减少的影响，博拓生物净利润同比大幅下滑。2024年第一季度，博拓生物业绩回升，报告期内流感相关产品收入增长，为营收增长提供动力。与此同时，博拓生物利息收入增长与销售收入增长，推动归母净利润的增长。随着临床试验投入增加，报告期内研发投入也同比增长48.23%。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"688767":"博拓生物"},"translate_title":"Botuo Biotech's net profit attributable to the parent company in the first quarter of this year increased by 233.05% year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688767":1},"content_text":"新京报讯（记者王卡拉）4月27日，博拓生物发布2024年一季报，报告期内实现营收1.36亿元，同比增长30.81%；归属于上市公司股东的净利润为3963.13万元，同比增长233.05%。归属于上市公司股东的扣除非经常性损益的净利润同比增长335.55%。2023年，受新冠疫情常态化后新冠检测试剂产品销售收入同比大幅减少的影响，博拓生物净利润同比大幅下滑。因市场需求发生变化，博拓生物部分生产设备出现闲置状况，部分存货可变现净值低于账面价值，博拓生物计提资产减值损失和信用减值损失合计5883.64万元。这一年，博拓生物抓住过国内甲乙流感高发期间相关检测试剂产品的增长需求，拓展国内市场和提升品牌影响力。如果剔除新冠检测产品影响，博拓生物常规产品销售收入同比稳步增长。4月25日，博拓生物董事会会议通过2023年度利润分配预案，拟向全体股东每10股派发现金股利8元（含税），共计8364.55万元（含税）。2024年第一季度，博拓生物业绩回升，报告期内流感相关产品收入增长，为营收增长提供动力。与此同时，博拓生物利息收入增长与销售收入增长，推动归母净利润的增长。随着临床试验投入增加，报告期内研发投入也同比增长48.23%。校对 卢茜","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2430054133"}